Empagliflozin/linagliptin/metformin

< Empagliflozin < linagliptin

Empagliflozin/linagliptin/metformin
Combination of
EmpagliflozinSGLT2 inhibitor
LinagliptinDPP-4 inhibitor
MetforminAnti-diabetic biguanide
Clinical data
Trade namesTrijardy XR
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a fixed-dose combination medication used for the treatment of type 2 diabetes. It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.